Problems of Radiation Medicine and Radiobiology

D. Bazyka¹, M. Vorobyov², I. Kechyn³, O. Vorobyov², O. Shmykova²

¹State Institution «National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka St., Kyiv, 04050, Ukraine
²Municipal Enterprise «Zaporizhzhya Regional Clinical Oncology Center» Zaporizhzhya regional Council, 177а Kulturna St., Zaporizhzhia, 69040, Ukraine
³Zaporizhzhia State Medical University, 26 Maiakovskyi Ave., Zaporizhzhia, 69035, Ukraine

RADIOTHERMOMETRIC PERSONALISATION OF CHEMO- AND RADIOTHERAPY FOR PATIENTS WITH ADVANCED (III, IVA AND IVB) STAGES MALIGNANT LESIONS OF ORAL CAVITY, THROAT AND EPIGLOTTIS

Objective. optimization of treatment of patients with advanced malignant lesions of oral cavity, throat and epiglottis by means of radiothermic control and personalisation of the induction radio sensitizing polychemotherapy prior to radiotherapy or by applying both methods simultaneously.
Materials and methods. Study is based on the results of treatment 280 patients with morphologically confirmed cancer of mucosae of oral cavity, throat and epigloittis staged III, IVA and IVB without remote metastases were divided into 6 groups depending on a type of a radiotherapy applied. Each group was divided into a treatment and a control subgroup. A choice of treatment for control subgroups was done on the basis of RECIST 1.1. scale; a decision for treatment subgroups was done based on obtained radiothermic (RTM) personalisation data in tumours or metastases.The treatment program included follow-ups according to established guidelines, radiothermic measurements, immunology investigations , statistical analysis (cumulative survival by Kaplan-Meier).
Results. Groups of patients with tumours of oral cavity and epigloittis with intra-arterial polychemotherapy (IA PCT) prior to radiotherapy demonstrated improved mean 3 years survival rate. Groups with malignant tumours of upper laryngeal tract demonstrated opposite results. A comparison of mean survival rates between groups that were treated with systemic radiochemotherapy but using different combinations of different chemotherapy agents has shown that a use of polyplatilen is superior to combinations with cisplatin. A further study showed that all treatment groups had demonstrated better survival rates compared to control groups.
Conclusions. The obtained results allow us to conclude that the therapy personalisation based on radiothermic personalisation significantly improves quality and outcomes for patients with localized cancer of oral cavity, throat and epiglottis. RTP can be used as a treatment control method of above mentioned lesions together with standard treatment pathways. The application of intra-arterial polychemotheray followed by a radiotherapy of tumours of oral cavity and throat shows better outcomes compared to standard treatments only. The use of induction polychemotherapy with polyplatilene for patients with tumours of epiglottis is superior to intra-arterial polychemotherapy and a chemotherapy with cisplatin.
Key words: malignant lesions of oral cavity, throat and epiglottis, radiochemotherapy, radiothermic measurements.

Problems of Radiation Medicine and Radiobiology.
2019;24:296-311. doi: 10.33145/2304-8336-2019-24-296-311

full text

1. Paches AI, Pustynskij IN, Demidov LV. [Tumors of the head and neck]. Moscow: Practical medicine; 2013. 480 p. Russian.

2. Feller L, Lemmer J. Oral squamous cell carcinoma: epidemiology, clinical presentation and treatment. J Cancer Ther. 2012;3:263-8. DOI: 10.4236/jct.2012.34037.

3. Fedorenko ZP, Mihajlovich JuJ, Gulak LO, Goroh EL, Rizhov AJu, Sumkina OV, et al.; Kolesnik EA, editor [Cancer in Ukraine, 2013–2014.]. Bulletin of the National Chancery Register of Ukraine. Kyiv: NCI; 2015. No. 16 106 p. Ukrainian.

4. Choynozov EL, Shishkin DA, Shishkin AA. [Chemoradiation component of a combined treatment of oropharyngeal cancer]. Malignant Tumours. 2013;2:94. Russian.

5. Bernier J, Cooper JS, Pajak TF, Van Glabbeke M, Bourhis J, Forastiere AA et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head and Neck. 2005 Oct;27(10):843-850. DOI: https://doi.org/10.1002/hed.20279.

6. Chen PY, Chen HH, Hsiao JR, YangMW, Hsueh WT, Tasi ST, et al. Intensity-modulated radiotherapy improves outcomes in postoperative patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2012 Aug;48:747–752. DOI: https://doi.org/10.1016/j.oraloncology.2012.02.010.

7. Pankratov VA. [Chemotherapy with the use of physical radiomodification in the treatment of patients with locally advanced laryngeal cancer] [dissertation]. Obninsk: Obninsk Medical Radiological Research Center, 2010. 216 p. Russian.

8. Donald PJ. The difficult case in head and neck cancer surgery. New York: Thieme Medical Publishers; 2010. 560 p.

9. Leemans R. Strategies for non-resectable tumors. In: 3rd Trends in Head and Neck Oncology (THNO); 3-5 Nov 2011; Rome, Italy. Rome; 2011. p. 17-24.

10. Pignon JP, leMaitre A, Maillard E. Meta-analysis of chemotherapy in head and neck cancer (MACH–NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14. DOI: https://doi.org/10.1016/j.radonc.2009.04.014.

11. Alieva SB. [Chemotherapy of patients with locally advanced squamous cell carcinoma of the head and neck]. Practical oncology. 2008;9(1):27–30. Russian.

12. Cohen EE, Baru J, Huo D, Haraf D J, Crowley M, Witt ME, et al. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug;31:1013–1021. DOI: https://doi.org/10.1002/hed.21062.

13. Argiris A, Karamouzis MV, Raben D. Head and neck cancer. Lancet. 2008;371(9625):1695–1709. DOI:https://doi.org/10.1016/S0140-6736(08)60728-X.

14. Vihljanov IV. [Optimization of complex treatment of oral squamous cell carcinoma and oral pharynx] [dissertation]. Barnaul: Altai State Medical University, 2005. 288 p. Russian.

15. Huang TY, Hsu LP, Wen YH, Huang TT, Chou YF, Lee CF, et al. Predictors of locoregional recurrence in early stage oral cavity cancer with free surgical margins. Oral Oncol. 2010;46:49–55. DOI: https://doi.org/10.1016/j.oraloncology.2009.10.011

16. Korobko EV, Procyk VS. [The use of induction chemotherapy in the complex treatment of patients with oral cancer, taking into account immunohistochemical factors]. Clin Oncol. 2015;4:33–38. Ukrainian.

17. Mami-Chouaib F, Echchakir H, Dorothee G, Vergnon I, Chouaib S. Antitumor cytotoxic T-limphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev. 2002 Oct;188(1):114–121. DOI: https://doi.org/10.1034/j.1600-065X.2002.18810.x.

18. Ochsenbien AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hengartner H, et al. Roles of tumor localization, second signal and cross priming in cytotoxic T-cell induction. Nature. 2001 Jun;411(6841):1058-64.

19. Barrett A, Myers PC, Sadowsky NL. Detection of breast cancer by microwave radiometry. Radio Sci. 1977 Nov;12(167):167–171. DOI: https://doi.org/10.1029/RS012i06Sp00167.

20. Buvaev SI. [Optimization of preclinical and clinical verification of the larynx cancer metastasis in the neck regional lymphatic nodes with the use of profunding radiothermometry] [dissertation]. Bishkek: Akhunbayeva Kyrgyz State Medical Academy, 2011. 118 p. Russian.

21. Shmikova EV. [The role of chronochemotherapy in conservative treatment of patients with non-resectable breast cancer] [dissertation]. Donetsk: Gorky Donetsk National Medical University, 2012. 140 p. Ukrainian.